



Published in final edited form as:

*Breast Cancer Res Treat.* 2018 December ; 172(3): 647–657. doi:10.1007/s10549-018-4932-6.

## Obesity and mortality after locoregional breast cancer diagnosis

A. Holliston Moore<sup>1,13,14</sup>, Amy Trentham-Dietz<sup>1,4</sup>, Marguerite Burns<sup>1</sup>, Ronald E. Gangnon<sup>1,3</sup>, Caprice C. Greenberg<sup>2,4</sup>, David J. Vanness<sup>15</sup>, John Hampton<sup>4</sup>, Xiao-Cheng Wu<sup>5</sup>, Roger T. Anderson<sup>6</sup>, Joseph Lipscomb<sup>7</sup>, Gretchen G. Kimmick<sup>8</sup>, Rosemary Cress<sup>9</sup>, J. Frank Wilson<sup>10</sup>, Susan A. Sabatino<sup>11</sup>, and Steven T. Fleming<sup>12</sup>

<sup>1</sup>Department of Population Health Sciences, University of Wisconsin, Madison, WI, USA

<sup>2</sup>Department of Surgery, University of Wisconsin, Madison, WI, USA

<sup>3</sup>Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USA

<sup>4</sup>University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI, USA

<sup>5</sup>Louisiana State University Health Sciences Center, New Orleans, LA, USA

<sup>6</sup>University of Virginia School of Medicine, Charlottesville, VA, USA

<sup>7</sup>Rollins School of Public Health and Winship Cancer Institute, Emory University, Atlanta, GA, USA

<sup>8</sup>Duke University Medical Center, Durham, NC, USA

<sup>9</sup>Public Health Institute, Cancer Registry of Greater California, Sacramento, USA

<sup>10</sup>Medical College of Wisconsin, Milwaukee, WI, USA

<sup>11</sup>Centers for Disease Control and Prevention, Atlanta, GA, USA

<sup>12</sup>University of Kentucky College of Public Health, Lexington, KY, USA

<sup>13</sup>University of Wisconsin, 307 WARF Building, 610 Walnut St, Madison, WI 53726, USA

<sup>14</sup>Present Address: Smith Cardiovascular Research Building, University of California San Francisco, 555 Mission Bay Blvd S, Suite 161, San Francisco, CA 94158, USA

<sup>15</sup>Department of Health Policy and Administration, The Pennsylvania State University, University Park, PA, USA

### Abstract

**Purpose**—Higher mortality after a breast cancer diagnosis has been observed among women who are obese. We investigated the relationships between body mass index (BMI) and all-cause or breast cancer-specific mortality after a diagnosis of locoregional breast cancer.

---

A. Holliston Moore ahmoore2@wisc.edu.

Compliance with ethical standards

**Conflict of interest** The authors declare they have no conflict of interest.

**Electronic supplementary material** The online version of this article (<https://doi.org/10.1007/s10549-018-4932-6>) contains supplementary material, which is available to authorized users.

**Methods**—Women diagnosed in 2004 with AJCC Stage I, II, or III breast cancer ( $n = 5394$ ) were identified from a population-based National Program of Cancer Registries (NPCR) patterns of care study (POC-BP) drawing from registries in seven U.S. states. Differences in overall and breast cancer-specific mortality were investigated using Cox proportional hazards regression models adjusting for demographic and clinical covariates, including age- and stage-based subgroup analyses.

**Results**—In women 70 or older, higher BMI was associated with lower overall mortality (HR for a 5 kg/m<sup>2</sup> difference in BMI = 0.85, 95% CI 0.75–0.95). There was no significant association between BMI and overall mortality for women under 70. BMI was not associated with breast cancer death in the full sample, but among women with Stage I disease; those in the highest BMI category had significantly higher breast cancer mortality (HR for BMI ≥ 35 kg/m<sup>2</sup> vs. 18.5–24.9 kg/m<sup>2</sup> = 4.74, 95% CI 1.78–12.59).

**Conclusions**—Contrary to our hypothesis, greater BMI was not associated with higher overall mortality. Among older women, BMI was inversely related to overall mortality, with a null association among younger women. Higher BMI was associated with breast cancer mortality among women with Stage I disease, but not among women with more advanced disease.

### Keywords

Breast cancer; Obesity; Breast cancer mortality; All-cause mortality

---

### Introduction

Although breast cancer treatment advances have substantially reduced mortality among the population of affected women, research suggests that disparities in relative mortality between obese and non-obese patients persist. A substantial amount of evidence suggests not only that obesity is associated with risk of developing breast cancer among post-menopausal women [1], but that women of all ages who have developed breast cancer are likely to have higher mortality if they are obese [2–26]. Given the increasing proportion of breast cancer patients who are obese, characterizing these disparities and exploring potential mechanisms behind them is important.

Existing literature suggests that higher body mass index (BMI) at diagnosis is associated with greater risk of death from any cause following a breast cancer diagnosis [3–5, 7, 9, 16, 27, 28]. Some studies indicate that this association may differ according to patient characteristics, and may not be present in all subgroups [3, 14, 28–31]. Many studies reported a U-shaped curve, with underweight patients also at higher risk of death from any cause [7]. However, taken as a whole, the existing literature strongly indicates that, with the potential exception of underweight individuals, women with higher BMI are at higher risk of all-cause mortality following a breast cancer diagnosis.

In addition to the observed relationship between higher BMI and overall mortality, a substantial amount of literature suggests that higher BMI is related specifically to death from breast cancer [7, 13, 14, 25, 26, 28]. A smaller number of studies indicate, in contrast, that

obesity is not associated with breast cancer-specific mortality [9, 32], or that the association may be present only among women in certain age-related subgroups [33, 34].

The observed pattern of higher breast cancer-specific mortality in obese patients likely reflects multiple factors. Obesity is associated with multiple physiological risk factors for breast cancer mortality, including chronic inflammation [35]; higher levels of endocrine factors, such as insulin, insulin-like growth factor, and estrogen, which are thought to promote tumor progression [35–37]; and altered production of the adipokines leptin and adiponectin (increased leptin and decreased adiponectin have been found to contribute to tumor growth) [35, 37]. Obese patients frequently have larger tumors at treatment onset due in part to delayed diagnosis, perhaps due to differences in screening patterns [35, 38–40]. Additionally, systematic differences in the postsurgical treatment received by patients with higher and lower BMI—such as appropriate dosing of chemotherapy, as well as other potential differences—may exist [25, 41–44]. Some of these differences may also be related to sociodemographic and clinical factors closely correlated with BMI. It is therefore important to examine the relationship between BMI and breast cancer mortality over an extended time period, in a diverse population, accounting for potentially influential sociodemographic and clinical characteristics, in order to attempt to isolate the independent effect of adiposity on breast cancer mortality.

We compared overall mortality and breast cancer-specific mortality according to BMI using data on female breast cancer patients identified from population-based cancer registries in seven states, hypothesizing that breast cancer-specific mortality would be higher among women with higher BMI and that overall mortality would be higher among both underweight and obese women.

## Data and methods

### Data sources

This study used data from the National Program of Cancer Registries (NPCR) Breast and Prostate Cancer Data Quality and Patterns of Care Study (POC-BP) to examine the relationships between patient BMI and mortality after breast cancer diagnosis. POC-BP data comprised breast and prostate cancer cases diagnosed in 2004 identified from population-based cancer registries in California, Georgia, Kentucky, Louisiana, Minnesota, North Carolina, and Wisconsin. Registry information was supplemented with data abstracted from medical records in hospitals and physicians' offices. Follow-up data on women's vital status were collected through the routine linkage of cancer registry data with death certificate data from state vital statistics departments, and through the use of the National Death Index (NDI) [45].

### Eligibility criteria

Women aged 20 or older diagnosed with primary breast cancer in 2004 (other than by autopsy or death certificate) were included in the POC-BP if they had no previous diagnoses of in situ or invasive breast cancer, other reportable cancers, Paget's disease, Kaposi's sarcoma, or lymphoma. Cases were selected from registries using random sampling

stratified by race/ethnicity, as well as Appalachian/non-Appalachian region in North Carolina and Kentucky, facility type and volume in Wisconsin, and urban-rural status in Georgia.

This analysis focused on locoregional disease. A total of 6967 patients with Stage I, II, or III disease were identified. Women who did not receive any surgery for their breast cancer ( $n = 105$ ), women with no vital status follow-up data ( $n = 6$ ), and women with unknown BMI ( $n = 1462$ ) were excluded, leaving 5394 cases.

### Explanatory variables

Body mass index ( $\text{kg}/\text{m}^2$ ) was calculated based on weight and height, measured at the time of diagnosis, abstracted from physicians' records.

### Outcomes

Time to death (all-cause or overall mortality) was defined as days between diagnosis and death from any cause. Time to death from breast cancer was defined as days between diagnosis and breast cancer-specific death, as determined from ICD-10 codes in registry databases; we identified breast cancer deaths based on the presence of a primary cause-of-death code of C509. As a comparison, time to death from a cause other than breast cancer, as determined from the ICD-10 codes, was also examined. Survival analyses included data on women's vital status through 8 years after the date of diagnosis (2004–2012). All registries contributed at least 5 years' worth of vital status data, with some contributing up to 8 years.

### Clinical and demographic covariates

Patient age was determined at time of diagnosis. Race/ethnicity information was obtained from patients' medical records, and from information found in Indian Health Services patient registration. When Hispanic origin was unclear, a North American Association of Central Cancer Registries identification algorithm was used [45].

Insurance status was categorized as private, Medicare or other public insurance only, Medicaid, uninsured, or unknown. The "private" category included patients with Medicare plus private supplemental insurance. Women who were dual-eligible for Medicare and Medicaid were grouped in the Medicaid category.

Education and socioeconomic status were based on census-tract information. Patients were categorized as living in a higher poverty (  $\geq 20\%$  of residents below the federal poverty level) or lower-poverty area, and as living in a lower-education (  $\geq 25\%$  of adults age 25 or older with less than high-school education) or higher-education area. Residential areas were described as 100% urban, mixed, or 100% rural, using the 2000 U.S. Census Bureau's urban and rural criteria [46].

Tumor pathologic stage was categorized as I, II, or III, as defined by American Joint Committee on Cancer (AJCC) staging criteria. Tumor grade was characterized by a I–IV score based on degree of cell differentiation, or as unknown. Estrogen receptor (ER) and progesterone receptor (PR) status were classified as positive (borderline was counted as positive), negative, or unknown.

A modification of the Piccirillo, or Adult Comorbidity Evaluation (ACE-27), comorbidity index [47] considered each of the 25 conditions (26 from the Piccirillo index, minus obesity, and not including the index breast cancer) and assigned a 1–3 score for “level of decompensation,” with 1 being “mild,” 2 “moderate,” and 3 “severe.” The overall comorbidity score was either based on the single highest ranking condition or assigned a value of 3 if the highest ranking ailments were grade 2 but occurred in different organ systems.

### Statistical analysis

Age-adjusted, survey-weighted linear regression analyses were conducted to examine associations between BMI and other demographic and clinical variables. Next, overall mortality and breast cancer-specific mortality were compared across BMI categories, based on cutoffs defined by the World Health Organization (“underweight” if BMI < 18.5 kg/m<sup>2</sup>, “normal” if BMI was 18.5–24.9 kg/m<sup>2</sup>, “overweight” if BMI was 25.0–29.9 kg/m<sup>2</sup>, “obese” if BMI was 30.0–34.9 kg/m<sup>2</sup>, and “very obese” if BMI ≥ 35 kg/m<sup>2</sup>). Hazard ratios (HR) and 95% confidence intervals (CI) for each outcome were estimated using Cox proportional hazards models with survey weights and stratification to account for POC-BP sampling. Covariates were chosen a priori because of a known or potential relationship with BMI, and included race/ethnicity, health insurance, education, socioeconomic status, tumor registry, urban/rural residence, tumor size, tumor grade, hormone receptor status, and comorbidity. As a comparison, non-breast cancer mortality was examined in the same fashion. We calculated *p* values for linear trend by running a second version of each model, in which BMI was represented by a continuous variable.

### Results

Table 1 shows BMI according to demographic and clinical characteristics. The mean BMI was 29.1 kg/m<sup>2</sup> and the median, 28.0 kg/m<sup>2</sup>. Age at diagnosis ranged from 20 to 98 years. Age and BMI at time of diagnosis were associated (*p* < 0.001); mean BMI was greater in higher age categories, except among women aged 70–79 and women aged 80 or older.

Race/ethnicity was associated with BMI (*p* < 0.001), with black women having the highest mean BMI (31.0 kg/m<sup>2</sup>) and Asian/Pacific Islander women having the lowest (24.4). Insurance type was also associated with BMI (*p* < 0.001); women with private insurance had the lowest mean BMI (27.9 kg/m<sup>2</sup>), while women insured through Medicaid had the highest (29.8 kg/m<sup>2</sup>). Women in higher-education census tracts and in lower-poverty census tracts tended to have lower BMI (*p* < 0.001 for both). Women in urban areas had the lowest mean BMI, and women in rural areas, the highest (*p* = 0.01). State of residence was also associated with BMI (*p* < 0.001).

Most women had AJCC stage I (48.4%) or stage II (37.6%) disease. A more detailed description of AJCC stage at diagnosis according to BMI category is available as Supplement 1. Higher AJCC stage and larger tumor size were associated with higher BMI (*p* < 0.001 for both).

Most patients (90%) had either no comorbid conditions or mild comorbidity. Comorbidity burden was associated with BMI, although not linearly. The lowest mean BMI was among women with a comorbidity score of 0 (26.4 kg/m<sup>2</sup>), and the highest among women with a score of 1 (30.0 kg/m<sup>2</sup>).

Five-year all-cause mortality was 14% and five-year breast cancer-specific mortality was 9.5%. All registries provided vital status data through the five-year post-diagnosis time point, with some providing vital status data for longer, up to eight years. At eight years after diagnosis, 19.2% of women were known to be deceased (1,033 deaths), with half of these deaths from breast cancer (514 breast cancer deaths, 49.8%), and the remainder (all but five) had been censored because vital status data were no longer being collected (Supplement Table 2).

Table 2 shows results of proportional hazards regression models investigating the relationship between BMI and all-cause, breast cancer-specific, or non-breast cancer mortality. Estrogen receptor status was not found to be strongly associated with mortality (Supplement Table 5).

### All-cause mortality

After adjusting for clinical and demographic characteristics, obese women with a BMI of 30–34.9 kg/m<sup>2</sup> appeared to have a lower hazard for all-cause mortality (HR for a 5 kg/m<sup>2</sup> difference in BMI = 0.93, 95% CI, 0.87–0.95; *p* value for trend = 0.02). However, the association between BMI and all-cause mortality was found to vary according to age at diagnosis (Table 3); *p* value for interaction = 0.01). Among women in the under-50 and 50–69 age groups, there was no significant association between BMI and overall mortality, but among women 70 and older, BMI was inversely related to overall mortality (*p* value for trend = 0.01). In particular, among those 70 or older, women with BMI < 18.5 kg/m<sup>2</sup> had a significantly elevated mortality hazard compared to women with a BMI of 18.5–24.9 kg/m<sup>2</sup> (HR = 1.92, 95% CI 1.11–3.34) and there was a suggestion that women in higher BMI categories had a lower mortality hazard (HR for BMI of 25–29.9 kg/m<sup>2</sup>, 30–34.9 kg/m<sup>2</sup>, and 35 kg/m<sup>2</sup> compared to women with a BMI of 18.5–24.9 kg/m<sup>2</sup> = 0.84, 0.73, and 0.78, respectively; 95% CIs 0.63–1.14, 0.51–1.05, and 0.52–1.17, respectively). In an analysis (not shown) in which women over 70 were examined after excluding underweight women, the association between higher BMI and lower overall mortality hazard remained significant as gaged by the *p* value for linear trend (*p* = 0.02), with hazard ratios for the overweight, obese, and very obese categories similar to those found in all women over 70 (0.84, 0.77, and 0.84, respectively).

In models stratified according to AJCC stage (Table 4), no significant differences were observed in the HR estimates for each stage, and indeed within each stage-specific model, the BMI-overall mortality relationship was not significant. There was no significant interaction between BMI and AJCC stage with regard to all-cause mortality (*p* = 0.83). In models stratified according to estrogen receptor status (Supplement Table 6), there was a suggestion that higher BMI might be inversely associated with lower all-cause mortality among women with ER-positive tumors (*p* value for trend = 0.03). Among women with ER-negative tumors, no significant overall association was found (*p* value for trend = 0.22).

There was no significant interaction between ER status and BMI with regard to all-cause mortality ( $p = 0.29$ ).

We explored whether the association between BMI and all-cause mortality might vary according to race/ethnicity or tumor registry. No significant interactions were observed.

### Breast cancer mortality

BMI was not found to be associated with breast cancer-specific mortality in the overall model (Table 2). However, in models stratified according to AJCC stage (Table 5), specifically among patients with Stage I tumors, higher BMI was associated with greater breast cancer mortality hazard—in particular, women with BMI  $\geq 35$  kg/m<sup>2</sup> were found to have over four times the breast cancer mortality hazard (HR = 4.74, 95% CI 1.78–12.59) of women with a BMI of 18.5–24.9 kg/m<sup>2</sup>. Among women with Stage II or III tumors, no relationship between BMI and breast cancer mortality was observed.

The association between BMI and breast cancer mortality was not found to differ according to age, estrogen receptor status (Supplement Table 7), race/ethnicity, or tumor registry.

### Non-breast cancer mortality

Results for models of non-breast cancer mortality were generally similar to those for all-cause mortality (Table 2, Supplement Table 3, Supplement Table 4), including a significant inverse association between BMI and non-breast cancer mortality among women 70 or older (Supplement Table 3). The association between BMI and non-breast cancer mortality was not found to differ according to estrogen receptor status (Supplement Table 8;  $p = 0.35$  for interaction).

## Discussion

In this study, we examined all-cause mortality and breast cancer mortality according to BMI among women with locoregional disease followed for five to eight years after diagnosis. Our findings largely differed from the hypotheses we had laid out, in that higher BMI was not consistently associated with higher overall mortality hazard, and was associated with higher breast cancer mortality hazard among only those women with AJCC Stage I disease. We discuss these findings in greater detail below.

Contrary to our hypotheses, higher BMI was not associated with higher overall mortality, and was actually associated with lower overall mortality hazard among women age 70 or older. Among women in this age category, all-cause mortality hazard was substantially higher among underweight women, but the association between BMI and mortality remained in an analysis excluding women who were underweight. It is possible that our method of adjusting for comorbidities did not completely capture comorbidity burden; older women with lower BMI, particularly women who were underweight, may have been more likely to have had undiagnosed comorbid conditions not accounted for in the Piccirillo index framework, or to be smokers. However, poorer outcomes related to being underweight do not entirely explain the observed association—that is, having higher BMI, rather than simply not being underweight, may have a protective effect. This finding is in line with previous

research documenting an inverse relationship between BMI and mortality among older individuals in the general population, a pattern referred to as an “obesity paradox” or “reverse epidemiology” [48].

It is nevertheless surprising, given previous findings, that there was a null relationship between BMI and all-cause mortality among women under age 70. Where differences in the BMI-mortality relationship according to age have been examined, some other researchers have found the relationship between BMI and mortality to differ according to age [3, 23]; however, among these studies, a null BMI-mortality association among younger women and inverse association among older women was not observed. Rather, higher BMI was found to be associated with poorer outcomes among younger women, with no significant relationship among older women.

Our findings regarding breast cancer-specific mortality were, as mentioned earlier, also surprising. In the full analytic sample and in most subsamples, higher BMI was not associated with higher mortality from breast cancer. We observed an exception to this finding in women with AJCC Stage I cancer; those in the highest BMI category (BMI of 35 kg/m<sup>2</sup> or greater) had a substantially greater hazard for breast cancer mortality. Notably, we did not observe a difference in the BMI-breast cancer mortality relationship according to age, in contrast to our findings regarding overall mortality.

The finding that BMI was associated with breast cancer mortality only among women with lower-stage disease contrasts with some previous findings [5, 7, 9, 11, 13, 21], but is also consistent with a number of previous reports finding, for example, that BMI was significantly associated with breast cancer death only among women with less advanced disease [15, 49] or with no positive lymph nodes [50]. Some of the earliest studies reported a similar pattern [51, 52], prompting authors to suggest that effects of BMI are more apparent among women with generally better prognostic features. This is perhaps the most likely explanation, but further research could address whether other factors contribute. Women with higher BMI and less advanced disease may be less likely to receive adjuvant chemotherapy or hormonal therapy in line with recommendations. Alternatively or in addition to this potential contributor, women with higher BMI may be more likely to erroneously have their disease characterized as less advanced, due to technical challenges with staging procedures [49]. The possibility of statistical artifacts related to this issue needs to be considered in future study designs. As technologies make accurate staging easier, and as research continues to identify prognostic features beyond TNM stage, it will also be important to consider whether an apparent association remains between BMI and disease-specific mortality among women with an earlier assigned tumor stage, or in otherwise-defined favorable prognostic categories.

### Strengths and limitations

In our analyses, we made use of a large sample of patients all diagnosed in the same year with locoregional disease, representing diverse geographic areas, racial/ethnic categories, and socioeconomic characteristics. The POC-BP data set was more complete than some registry-based studies due to additional resources made available to the investigators to verify data and collect more detailed information; thus, the study benefited from

meticulously collected comorbidity and staging data. The study benefited from a relatively long follow-up period, with up to eight years of data from most of the tumor registries represented.

This study's findings need to be considered in light of some limitations. Not all registries collected and provided data for the same length of time. Follow-up data for the full 8 years for all women would have improved statistical power, but we do not consider it likely that differences in follow-up duration by registry biased our results, because our statistical models accounted for tumor registry. Additionally, despite POC-BP study oversampling, there were low numbers of women in some racial/ethnic subgroups. We also could not investigate potential interactions according to menopausal status because data on menopausal status were not available. Additional data that were not available as part of the data set include information on women's smoking status and concomitant medication use.

BMI is not a precise or consistent means of characterizing adiposity [53, 54]; it is problematic at the extremes of height, and may exhibit systematically larger inaccuracies among older women [53]. Some researchers have therefore leaned away from BMI in favor of measures such as waist-to-hip ratio. However, BMI is still frequently used, as in this retrospective analysis, in the absence of other available measures.

Missing data on height and/or weight pose a potential threat to the validity of our findings because they are unlikely to be missing at random. 21.3% of the women in the parent data set who were eligible to be included in the analytic data set were excluded due to missing information on weight, height, or both. We conducted a sensitivity analysis in which missing weight or height was imputed among women whose records showed one but not the other. Findings (not shown) were very similar to those from our main analyses reported here.

## Implications

Although our investigation did not replicate some previous findings linking greater BMI to higher breast cancer mortality in the general female breast cancer population, we did identify women with Stage I disease as a group in which obesity, particularly greater than moderate obesity, was strongly linked to poorer outcomes with regard to breast cancer death. With continued improvement in diagnostic techniques and screening practices, more women will likely be diagnosed with early-stage disease, making it even more important to understand and address the disparities in outcomes within this subgroup. Another notable finding was the inverse relationship between BMI and all-cause mortality among women above age 70. The average life span of women is now well above 70, and many women are diagnosed at a later age. It is therefore of critical importance to determine whether, perhaps due to differences in tumor characteristics, comorbidities, or other factors, body weight and adiposity may have differing effects on outcomes in this subgroup.

## Conclusion

This study examined overall mortality and breast cancer mortality among women with locoregional breast cancer. It adds to existing evidence by drawing on a population-based sample of women diagnosed with Stage I, II, or III disease in seven different geographic

regions and followed for five to eight years. Continued research examining the multifactorial relationships linking obesity and breast cancer outcomes, including factors that may modify these relationships, will be important in the ongoing effort to reduce the burden of disease from breast cancer.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements

The data used for this publication were collected by the Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries Patterns of Care Study for Breast and Prostate Cancers (POC-BP), which was funded by CDC through cooperative agreements with the participating state cancer registries including Grant U01DP000261. This study was supported in part by NIH Grant P50 CA14520. This manuscript is written on behalf of the POC-BP Collaborators. Findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The authors thank Jen Wike, Julie McGregor, Laura Stephenson, and the certified tumor registrars at all the study centers for assistance with study support and data collection.

## References

1. McTiernan A (2003) Behavioral risk factors in breast cancer: can risk be modified? *Oncologist* 8(4): 326 [PubMed: 12897329]
2. Abrahamson PE, Gammon MD, Lund MJ, Flagg EW, Porter PL, Stevens J et al. (2006) General and abdominal obesity and survival among young women with breast cancer. *Cancer Epidemiol Biomark Prev* 15(10):1871 10.1158/1055-9965.epi-06-0356
3. Berclaz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam CM et al. (2004) Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. *Ann Oncol* 15(6):875 [PubMed: 15151943]
4. Caan BJ, Kwan ML, Hartzell G, Castillo A, Slattery ML, Sternfeld B et al. (2008) Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer. *Cancer Causes Control* 19(10):1319 10.1007/s10552-008-9203-0 [PubMed: 18752034]
5. Dawood S, Broglio K, Gonzalez-Angulo AM, Kau SW, Islam R, Hortobagyi GN et al. (2008) Prognostic value of body mass index in locally advanced breast cancer. *Clin Cancer Res* 14(6):1718 10.1158/1078-0432.ccr-07-1479 [PubMed: 18347172]
6. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. *N Engl J Med* 348(17):1625 10.1056/NEJMoa021423 [PubMed: 12711737]
7. Chan DS, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A et al. (2014) Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. *Ann Oncol* 25(10):1901–1914. 10.1093/annonc/mdu042 [PubMed: 24769692]
8. Daling JR, Malone KE, Doody DR, Johnson LG, Gralow JR, Porter PL (2001) Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. *Cancer* 92(4):720 [PubMed: 11550140]
9. Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP (2003) Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. *J Natl Cancer Inst* 95(19):1467 [PubMed: 14519753]
10. Enger SM, Greif JM, Polikoff J, Press M. Body weight correlates with mortality in early-stage breast cancer. *Arch Surg (Chicago, Ill: 1960)*. 2004;139(9):954 10.1001/archsurg.139.9.954
11. Ewertz M, Jensen MB, Gunnarsdottir KA, Hojris I, Jakobsen EH, Nielsen D et al. (2011) Effect of obesity on prognosis after early-stage breast cancer. *J Clin Oncol* 29(1):25 10.1200/jco.2010.29.7614 [PubMed: 21115856]

12. Goodwin PJ, Boyd NF (1990) Body size and breast cancer prognosis: a critical review of the evidence. *Breast Cancer Res Treat* 16(3):205 [PubMed: 2085672]
13. Hellmann SS, Thygesen LC, Tolstrup JS, Gronbaek M (2010) Modifiable risk factors and survival in women diagnosed with primary breast cancer: results from a prospective cohort study. *Eur J Cancer Prev* 19(5):366 10.1097/CEJ.0b013e32833b4828 [PubMed: 20502344]
14. Kamineni A, Anderson ML, White E, Taplin SH, Porter P, Ballard-Barbash R et al. (2012) Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population. *Cancer Causes Control*. 10.1007/s10552-012-0115-7
15. Kroenke CH, Chen WY, Rosner B, Holmes MD (2005) Weight, weight gain, and survival after breast cancer diagnosis. *J Clin Oncol* 23(7):1370 10.1200/jco.2005.01.079 [PubMed: 15684320]
16. Kwan ML, Chen WY, Kroenke CH, Weltzien EK, Beasley JM, Nechuta SJ et al. (2011) Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project. *Breast Cancer Res Treat*. 10.1007/s10549-011-1914-3
17. Loi S, Milne RL, Friedlander ML, McCredie MR, Giles GG, Hopper JL et al. (2005) Obesity and outcomes in premenopausal and postmenopausal breast cancer. *Cancer Epidemiol Biomark Prev* 14(7):1686 10.1158/1055-9965.epi-05-0042
18. Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B (2008) Is obesity an independent prognosis factor in woman breast cancer? *Breast Cancer Res Treat* 111(2):329 10.1007/s10549-007-9785-3 [PubMed: 17939036]
19. Petrelli JM, Calle EE, Rodriguez C, Thun MJ (2002) Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. *Cancer Causes Control* 13(4):325 [PubMed: 12074502]
20. Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J (2010) Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. *J Clin Oncol* 28(21):3411 10.1200/jco.2009.27.2021 [PubMed: 20547990]
21. Nichols HB, Trentham-Dietz A, Egan KM, Titus-Ernstoff L, Holmes MD, Bersch AJ et al. (2009) Body mass index before and after breast cancer diagnosis: associations with all-cause, breast cancer, and cardiovascular disease mortality. *Cancer Epidemiol Biomark Prev* 18(5): 1403 10.1158/1055-9965.epi-08-1094
22. Tao MH, Shu XO, Ruan ZX, Gao YT, Zheng W (2006) Association of overweight with breast cancer survival. *Am J Epidemiol* 163(2):101 10.1093/aje/kwj017 [PubMed: 16339054]
23. Vitolins MZ, Kimmick GG, Case LD (2008) BMI influences prognosis following surgery and adjuvant chemotherapy for lymph node positive breast cancer. *Breast J* 14(4):357 10.1111/j.1524-4741.2008.00598.x [PubMed: 18540954]
24. Whiteman MK, Hillis SD, Curtis KM, McDonald JA, Wingo PA, Marchbanks PA (2005) Body mass and mortality after breast cancer diagnosis. *Cancer Epidemiol Biomark Prev* 14(8):2009 10.1158/1055-9965.epi-05-0106
25. Protani M, Coory M, Martin JH (2010) Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. *Breast Cancer Res Treat* 123(3):627 10.1007/s10549-010-0990-0 [PubMed: 20571870]
26. Niraula S, Ocana A, Ennis M, Goodwin PJ (2012) Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. *Breast Cancer Res Treat* 134(2):769 10.1007/s10549-012-2073-x [PubMed: 22562122]
27. Dignam JJ, Wieand K, Johnson KA, Raich P, Anderson SJ, Somkin C et al. (2006) Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer. *Breast Cancer Res Treat* 97(3):245 10.1007/s10549-005-9118-3 [PubMed: 16331345]
28. Kwan ML, John EM, Caan BJ, Lee VS, Bernstein L, Cheng I et al. (2014) Obesity and mortality after breast cancer by race/ ethnicity: the California Breast Cancer Survivorship Consortium. *Am J Epidemiol* 179(1):95–111. 10.1093/aje/kwt233 [PubMed: 24107615]
29. Ademuyiwa FO, Groman A, O'Connor T, Ambrosone C, Watroba N, Edge SB (2011) Impact of body mass index on clinical outcomes in triple-negative breast cancer. *Cancer*. 10.1002/cncr.26019
30. Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM (2012) Impact of body mass index on survival outcome among women with early stage triple-negative breast cancer. *Clin Breast Cancer* 12(5):364–372. 10.1016/j.clbc.2012.07.013 [PubMed: 23040004]

31. Tait S, Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX (2014) Body mass index, diabetes, and triple-negative breast cancer prognosis. *Breast Cancer Res Treat* 146(1):189–197. 10.1007/s10549-014-3002-y [PubMed: 24869799]
32. Katoh A, Watzlaf VJ, D'Amico F (1994) An examination of obesity and breast cancer survival in post-menopausal women. *Br J Cancer* 70(5):928 [PubMed: 7947099]
33. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D et al. (2007) Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. *BMJ* 335(7630):1134 10.1136/bmj.39367.495995.AE [PubMed: 17986716]
34. Eralp Y, Smith TL, Altundag K, Kau SW, Litton J, Valero V et al. (2009) Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. *J Cancer Res Clin Oncol* 135(1):141 10.1007/s00432-008-0428-9 [PubMed: 18581139]
35. Parekh N, Chandran U, Bandera EV (2012) Obesity in cancer survival. *Annu Rev Nutr.* 10.1146/annurev-nutr-071811-150713
36. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y et al. (2002) Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. *J Clin Oncol* 20(1): 42 [PubMed: 11773152]
37. Benedetto C, Salvagno F, Canuto EM, Gennarelli G (2015) Obesity and female malignancies. *Best Pract Res Clin Obstet Gynaecol.* 10.1016/j.bpobgyn.2015.01.003
38. Deglise C, Bouchardy C, Burri M, Usel M, Neyroud-Caspar I, Vlastos G et al. (2010) Impact of obesity on diagnosis and treatment of breast cancer. *Breast Cancer Res Treat* 120(1):185 10.1007/s10549-009-0459-1 [PubMed: 19597985]
39. Fair AM, Wujcik D, Lin JM, Grau A, Wilson V, Champion V et al. (2009) Obesity, gynecological factors, and abnormal mammography follow-up in minority and medically underserved women. *J Women's Health* 18(7):1033 10.1089/jwh.2008.0791
40. Olsson A, Garne JP, Tengrup I, Zackrisson S, Manjer J (2009) Body mass index and breast cancer survival in relation to the introduction of mammographic screening. *Eur J Surg Oncol* 35(12):1261 10.1016/j.ejso.2009.04.012 [PubMed: 19481409]
41. Hunter RJ, Navo MA, Thaker PH, Bodurka DC, Wolf JK, Smith JA (2009) Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA). *Cancer Treat Rev* 35(1):69 10.1016/j.ctrv.2008.07.005 [PubMed: 18922643]
42. Griggs JJ, Sabel MS (2008) Obesity and cancer treatment: weighing the evidence. *J Clin Oncol* 26(25):4060 10.1200/jco.2008.17.4250 [PubMed: 18757320]
43. Madarnas Y, Sawka CA, Franssen E, Bjarnason GA (2001) Are medical oncologists biased in their treatment of the large woman with breast cancer? *Breast Cancer Res Treat* 66(2):123 [PubMed: 11437098]
44. Dignam JJ, Mamounas EP (2004) Obesity and breast cancer prognosis: an expanding body of evidence. *Ann Oncol* 15(6):850 [PubMed: 15151938]
45. German RR, Wike JM, Bauer KR, Fleming ST, Trentham-Dietz A, Namiak M et al. (2011) Quality of cancer registry data: findings from CDC-NPCR's Breast and Prostate Cancer Data Quality and Patterns of Care Study. *J Regist Manag* 38(2):75
46. Census (2000) Urban and rural classification. <https://www.census.gov/geo/reference/ua/urban-rural-2000.html>
47. Piccirillo JF (2000) Importance of comorbidity in head and neck cancer. *The Laryngoscope* 110(4): 593 10.1097/00005537-200004000-00011 [PubMed: 10764003]
48. Ahmadi SF, Streja E, Zahmatkesh G, Streja D, Kashyap M, Moradi H et al. (2015) Reverse epidemiology of traditional cardiovascular risk factors in the geriatric population. *J Am Med Dir Assoc.* 10.1016/j.jamda.2015.07.014
49. Tretli S, Haldorsen T, Ottestad L (1990) The effect of pre-morbid height and weight on the survival of breast cancer patients. *Br J Cancer* 62(2):299 [PubMed: 2386747]
50. Newman SC, Lees AW, Jenkins HJ (1997) The effect of body mass index and oestrogen receptor level on survival of breast cancer patients. *Int J Epidemiol* 26(3):484 [PubMed: 9222771]

51. Hebert JR, Augustine A, Barone J, Kabat GC, Kinne DW, Wynder EL (1988) Weight, height and body mass index in the prognosis of breast cancer: early results of a prospective study. *Int J Cancer* 42(3):315–318 [PubMed: 3417358]
52. Boyd NF, Campbell JE, Germanson T, Thomson DB, Sutherland DJ, Meakin JW (1981) Body weight and prognosis in breast cancer. *J Natl Cancer Inst* 67(4):785–789 [PubMed: 6944548]
53. Shah NR, Braverman ER (2012) Measuring adiposity in patients: the utility of body mass index (BMI), percent body fat, and leptin. *PLoS ONE* 7(4):e33308. 10.1371/journal.pone.0033308
54. Thomas EL, Frost G, Taylor-Robinson SD, Bell JD (2012) Excess body fat in obese and normal-weight subjects. *Nutr Res Rev* 25(1):150–161. 10.1017/s0954422412000054 [PubMed: 22625426]

Breast cancer cases according to body mass index and other demographic and clinical characteristics; stages I, II, and III breast cancer patients from the POC-BP study (2004)

Table 1

Patient characteristic	No. <sup>a</sup> (N = 5394)	Weighted %	BMI (kg/m <sup>2</sup> )		p value <sup>b</sup>
			Mean	SE	
BMI category (kg/m <sup>2</sup> )					
<18.5	78	1.5			
18.5–24.9	1614	32.5			
25–29.9	1589	30.3			
30–34.9	1120	19.8			
35	960	15.8			
Demographic characteristics					
Age					
20–40	398	6.3	27.9	0.4	<0.001
40–49	1241	21.4	28.5	0.2	
50–59	1427	26.7	29.2	0.2	
60–69	1119	21.5	29.5	0.2	
70–79	823	16.3	28.0	0.2	
80	386	7.9	26.5	0.3	
Race					
White, non-Hispanic	3045	75.6	27.9	0.1	<0.001
Black, non-Hispanic	1486	13.9	31.0	0.2	
AI/AN, non-Hispanic	43	0.3	29.4	1.7	
API, non-Hispanic	315	3.6	24.4	0.5	
Hispanic	502	6.6	28.6	0.3	
Insurance					
Private	3238	62.9	27.9	0.1	<0.001
Medicare/other public	1083	21.2	28.3	0.2	
Medicaid	757	10.3	29.8	0.3	
None	158	2.0	28.4	0.6	
Unknown	158	3.7	28.7	0.5	
Census-tract education					
Higher	3286	69.2	27.8	0.1	<0.001

Patient characteristic	No. <sup>a</sup> (N = 5394)	Weighted %	BMI (kg/m <sup>2</sup> )		p value <sup>b</sup>
			Mean	SE	
Lower	2093	30.8	29.2	0.2	
Census-tract poverty					
Higher	4065	82.8	29.1	0.2	<0.0001
Lower	1314	17.2	28.1	0.1	
Urbanicity					
Urban	2773	52.5	28.0	0.1	0.01
Urban/rural mixed	1856	34.9	28.4	0.2	
Rural	751	12.7	28.9	0.3	
Registry (State)					
1	600	17.2	28.7	0.2	<0.0001
2	490	9.2	28.2	0.3	
3	577	11.2	28.5	0.3	
4	321	9.2	27.7	0.3	
5	983	8.7	29.2	0.3	
6	1298	18.6	28.7	0.2	
7	1125	25.9	27.5	0.2	
Clinical characteristics					
Tumor stage (AJCC)					
I	2509	48.4	27.6	0.1	<0.0001
II	2067	37.6	28.5	0.2	
III	818	14.0	29.4	0.2	
Lymph nodes					
Any positive	1920	33.9	28.9	0.2	<0.0001
All negative	3234	61.6	28.0	0.1	
Unknown	240	4.5	27.2	0.4	
Tumor size (cm)					
0.5	451	8.8	27.7	0.3	<0.0001
0.51–1	847	16.2	27.3	0.2	
1.01–2	1616	30.5	28.0	0.2	
2.01–5	2011	37.1	28.6	0.2	

Patient characteristic	No. <sup>a</sup> (N = 5394)	Weighted %	BMI (kg/m <sup>2</sup> )		p value <sup>b</sup>
			Mean	SE	
> 5	410	6.3	29.5	0.4	
Unknown	59	1.2	31.1	0.8	
Histologic type					
Ductal	3978	73.2	28.3	0.1	0.02
Lobular	373	7.3	28.4	0.3	
Mixed ductal/lobular	348	7.3	27.1	0.3	
Other	695	12.3	28.3	0.3	
Grade					
Well differentiated	943	19.0	27.6	0.2	0.07
Moderately differentiated	2051	39.0	28.2	0.2	
Poorly differentiated	2036	35.8	28.5	0.2	
Undifferentiated	62	1.0	28.6	0.9	
Unknown/other	302	5.1	28.6	0.4	
Hormone receptor status					
ER+ and/or PR+	3846	73.0	28.4	0.1	0.13
ER- and PR-	1316	22.5	27.9	0.2	
Unknown	232	4.5	27.7	0.4	
HER2 receptor status					
HER2+	1907	34.4	28.2	0.2	0.93
HER2-	2647	49.7	28.3	0.1	
Unknown	840	15.9	28.3	0.2	
Comorbidity					
None	2420	45.5	26.4	0.1	< 0.001
Mild	2440	44.0	30.0	0.1	
Moderate	373	7.4	29.3	0.3	
Severe	161	3.1	28.9	0.5	

AI/AN American Indian/Alaska Native, API Asian/Pacific Islander, ER+ estrogen receptor-positive, ER- estrogen receptor-negative, PR+ progesterone receptor-positive, PR- progesterone receptor-negative, HER2+ human epidermal growth factor 2 receptor-positive, HER2-human epidermal growth factor 2 receptor-negative

<sup>a</sup>Totals may not add up to 5394 due to missing values for some variables

$p$  values from general linear models comparing means between categories adjusted for age

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Hazard ratios (HR) and 95% confidence intervals (CI) for all-cause mortality, breast cancer-specific mortality, and non-breast cancer mortality according to body mass index

**Table 2**

	All-cause mortality			Breast cancer-specific mortality			Non-breast cancer mortality		
	HR	95% CI	<i>p</i> value <sup>a</sup>	HR	95% CI	<i>p</i> value <sup>a</sup>	HR	95% CI	<i>p</i> value <sup>a</sup>
Body mass index (kg/m <sup>2</sup> )									
< 18.5	1.31	0.80–2.15	<b>0.33</b>	<b>0.33</b>	0.12–0.93		<b>1.78</b>	1.09–2.95	
18.5–24.9	1 (ref)		1 (ref)	1 (ref)			1 (ref)		
25–29.9	0.82	0.67–1.01	0.87	0.87	0.40–1.19		0.82	0.63–1.06	
30–34.9	<b>0.75</b>	0.59–0.95	0.94	0.94	0.68–1.30		<b>0.67</b>	0.47–0.93	
35	0.85	0.67–1.08	0.93	0.93	0.64–1.35		0.88	0.64–1.21	
Per 5 kg/m <sup>2</sup>	<b>0.93</b> (0.87–0.95)		<b>0.02</b>	0.98 (0.94–1.02)		0.42	<b>0.90</b> (0.82–0.99)		<b>0.04</b>

Model adjusted for age, American Joint Commission on Cancer (AJCC) stage, insurance type, poverty in census tract of residence, education levels in census tract of residence, urbanicity of residence area, tumor grade, hormone receptor status, and comorbidity level. Survey sampling was stratified by tumor registry and by race/ethnicity

<sup>a</sup> *p* value for trend, calculated from model using BMI as a continuous measure

**Table 3**

Hazard ratios (HR) and 95% confidence intervals (CI) for all-cause mortality according to body mass index, stratified by age at time of diagnosis

	<i>N</i>	<u>All-cause mortality<sup>a</sup></u>		
		<b>HR</b>	<b>95% CI</b>	<i>p</i> value for trend
Under 50 years of age ( <i>N</i> = 1637)				
Body mass index (kg/m <sup>2</sup> )				
< 18.5	26	<b>0.10</b>	0.01–0.85	
18.5–24.9	585	1 (ref)		
25–29.9	408	0.94	0.59–1.51	
30–34.9	306	0.89	0.54–1.46	
35	312	1.04	0.63–1.73	
per 5 kg/m <sup>2</sup>		1.01	0.91–1.13	0.79
50–69 years of age ( <i>N</i> = 2541)				
Body mass index (kg/m <sup>2</sup> )				
< 18.5	26	1.05	0.36–3.04	
18.5–24.9	651	1 (ref)		
25–29.9	773	0.82	0.57–1.19	
30–34.9	581	0.77	0.52–1.13	
35	510	0.84	0.56–1.28	
Per 5 kg/m <sup>2</sup>		0.95	0.86–1.05	0.30
70 years of age or older ( <i>N</i> = 1201)				
Body mass index (kg/m <sup>2</sup> )				
< 18.5	25	<b>1.92</b>	1.11–3.34	
18.5–24.9	381	1 (ref)		
25–29.9	414	0.84	0.63–1.14	
30–34.9	239	0.73	0.51–1.05	
35	142	0.78	0.52–1.17	
per 5 kg/m <sup>2</sup>		<b>0.85</b>	0.75–0.95	<b>0.01</b>

*p* value for interaction term (age\*BMI) = 0.01

<sup>a</sup>Models adjusted for AJCC stage, insurance type, poverty in census tract of residence, education levels in census tract of residence, urbanicity of residence area, tumor grade, hormone receptor status, and comorbidity level. Survey sampling was stratified by tumor registry and by race/ethnicity

**Table 4**

Hazard ratios (HR) and 95% confidence intervals (CI) for all-cause mortality according to body mass index, stratified by AJCC stage at diagnosis

	<i>N</i>	<u>All-cause mortality<sup>a</sup></u>		
		<b>HR</b>	<b>95% CI</b>	<i>p</i> value for trend
Stage I ( <i>N</i> = 2504)				
Body mass index (kg/m <sup>2</sup> )				
< 18.5	40	<b>1.95</b>	1.03–3.69	
18.5–24.9	807	1 (ref)		
25–29.9	780	0.85	0.60–1.21	
30–34.9	495	0.71	0.48–1.06	
35	382	1.16	0.74–1.83	
Per 5 kg/m <sup>2</sup>		0.94	0.82–1.08	0.40
Stage II ( <i>N</i> = 2060)				
Body mass index (kg/m <sup>2</sup> )				
< 18.5	27	0.90	0.35–2.29	
18.5–24.9	594	1 (ref)		
25–29.9	584	0.77	0.55–1.08	
30–34.9	448	<b>0.66</b>	0.45–0.96	
35	407	0.84	0.58–1.23	
Per 5 kg/m <sup>2</sup>		0.93		0.17
Stage III ( <i>N</i> = 815)				
Body mass index (kg/m <sup>2</sup> )				
< 18.5	10	0.63	0.24–1.70	
18.5–24.9	216	1 (ref)		
25–29.9	231	0.73	0.49–1.08	
30–34.9	183	0.86	0.56–1.30	
35	175	0.70	0.44–1.11	
Per 5 kg/m <sup>2</sup>		0.92	0.83–1.02	0.11

A significant interaction between BMI and AJCC stage was not found ( $p = 0.83$ ); stratified analysis was conducted descriptively

<sup>a</sup>All models adjusted for age, insurance type, poverty in census tract of residence, education levels in census tract of residence, urbanicity of residence area, tumor grade, hormone receptor status, and comorbidity level. Survey sampling was stratified by tumor registry and by race/ethnicity

**Table 5**

Hazard ratios (HR) and 95% confidence intervals (CI) for breast cancer-specific mortality according to body mass index, stratified by AJCC stage at diagnosis

	N	Breast cancer-specific mortality <sup>a</sup>		
		HR	95% CI	p value for trend
Stage I (N= 2414)				
Body mass index (kg/m <sup>2</sup> )				
< 18.5	39	2.33	0.54–10.08	
18.5–24.9	788		1 (ref)	
25–29.9	739	1.47	0.67–3.20	
30–34.9	475	1.06	0.45–2.52	
35	373	<b>4.74</b>	1.78–12.59	
Per 5 kg/m <sup>2</sup>		<b>1.38</b> (1.22–1.55)		<b>0.004</b>
Stage II (N= 2060)				
Body mass index (kg/m <sup>2</sup> )				
< 18.5	27	Not estimable		0.51
18.5–24.9	594	1 (ref)		
25–29.9	584	0.88	0.53–1.47	
30–34.9	448	0.80	0.47–1.35	
35	407	0.87	0.48–1.58	
Stage III (N= 815)				
Body mass index (kg/m <sup>2</sup> )				
< 18.5	10	0.32	0.06–1.84	0.20
18.5–24.9	216	1 (ref)		
25–29.9	231	0.74	0.47–1.17	
30–34.9	183	0.97	0.62–1.54	
35	175	0.69	0.41–1.17	

p value for interaction term (stage\*BMI) = 0.04

<sup>a</sup>All models adjusted for age, insurance type, poverty in census tract of residence, education levels in census tract of residence, urbanicity of residence area, tumor grade, hormone receptor status, and comorbidity level. Survey sampling was stratified by tumor registry and by race/ethnicity